
SeQuent Scientific announces Q3 - FY 2014-15 Results

Consolidated Revenues at Rs.1119 mio

Revenue from continued operations grew by 10%

Bangalore, February 11, 2015, SeQuent Scientific Limited today announced its unaudited consolidated financial results for the quarter ended December 31, 2014.

Financial Highlights:

- Revenue from continued operations (excluding the divested Speciality Chemicals business) grew by 10%.

Operational Highlights:

- Supplies of Sofosbuvir commenced in January 2015 under the Licensing Agreement with Gilead Sciences from our USFDA approved facility at Mangalore.
- Alivira successfully completed customer audits of its new API facility at Vizag. Filings for regulated markets initiated.
- Alivira completed acquisition of majority stake in Provet Veterinary Products AS, Turkey on Nov 3, 2014 – Provet acquisition to accelerate Alivira's foray into global veterinary formulation market

Commenting on the occasion, Manish Gupta – Managing Director stated that “We had a subdued quarter, largely on account of slowdown in the demand for Anti-Malarial APIs. We are pleased that we could make our first supplies of Sofosbuvir within months of signing the Licensing Agreement with Gilead Sciences. We believe that Sofosbuvir would provide a significant opportunity for SeQuent to scale its business to next level.

About SeQuent Scientific Limited.

SeQuent Scientific Limited, listed on the Bombay Stock Exchange Limited (stock code: 512529) is an integrated pharmaceutical company operating in the domains of Animal Health (API and Formulations) and niche Human API's. The company has 8 manufacturing facilities based in India and Turkey and has approvals from global regulatory authorities including USFDA, WHO, EUGMP, etc.

Please visit www.sequent.in for additional information.

For additional information, please contact

SeQuent Scientific Limited

Manish Gupta, Managing Director

manish@sequent.in

Tel: +91 22 41114714

Kannan P R, CFO

Kannan.pr@sequent.in

Tel: +91 80 67840327

Mr. Rohit Yagnik, Fortuna PR

+91 98338 07272; rohit@fortunapr.in